Key result
Heterozygosity for the CLCN1 p.Phe413Cys mutation in patients with myotonic dystrophy type 2 exaggerates the severity of myotonia and contributes to phenotypic variability.
Observational
The coexistence of a CLCN1 mutation and CNBP expansion in the same family contributes to pronounced phenotypic variability and severity of myotonia.
May explain severe myotonia in some DM2 cases; leaves open whether CLCN1 testing should inform care.
Myotonia is characterized by hyperexcitability of the muscle cell membrane. Myotonic disorders are divided into two main categories: non-dystrophic and dystrophic myotonias. The non-dystrophic myotonias involve solely the muscle system, whereas the dystrophic myotonias are characterized by multisystem involvement and additional muscle weakness. Each category is further subdivided into different groups according to additional clinical features or/and underlying genetic defects. However, the phenotypes and the pathological mechanisms of these myotonic disorders are still not entirely understood. Currently, four genes are identified to be involved in myotonia: the muscle voltage-gated sodium and chloride channel genes SCN4A and CLCN1, the myotonic dystrophy protein kinase (DMPK) gene, and the CCHC-type zinc finger, nucleic acid binding protein gene CNBP. Additional gene(s) and/or modifying factor(s) remain to be identified. In this study, we investigated a large Norwegian family with clinically different presentations of myotonic disorders. Molecular analysis revealed CCTG repeat expansions in the CNBP gene in all affected members, confirming that they have myotonic dystrophy type 2. However, a CLCN1 mutation c.1238C>G, causing p.Phe413Cys, was also identified in several affected family members. Heterozygosity for p.Phe413Cys seems to exaggerate the severity of myotonia and thereby, to some degree, contributing to the pronounced variability in the myotonic phenotype in this family.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2010) conducted an observational in Myotonic disorders. CLCN1 mutation c.1238C>G (p.Phe413Cys) was evaluated on Severity of myotonia and phenotypic variability. Heterozygosity for the CLCN1 p.Phe413Cys mutation in patients with myotonic dystrophy type 2 exaggerates the severity of myotonia and contributes to phenotypic variability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: